Evidence map›Paper›PMID 31490545›Full record

ArticleInternational journal of cancer2020

Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.

Mark H Stoler, Ed Baker, Sean Boyle, Shagufta Aslam, Ruediger Ridder, Warner K Huh, Thomas C Wright

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06366516 (Clinical Validation of ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 Methylation in HPV Positive Women), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06366516 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Clinical Validation of ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 Methylation in HPV Positive Women: a Multi-center RCT From China

TypeinterventionalSponsorObstetrics & Gynecology Hospital of Fudan UniversityRan2024 to 2026Enrolled10,000ConditionsPrecancerous Cervical LesionArmsMethylation Test
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Role of p16/Ki67 Dual Staining in Cervical Cancer Screening.Current issues in molecular biology · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mark H StolerDepartment of Pathology, University of Virginia Health System, Charlottesville, VA.ORCID 0000-0001-7738-7336
Ed BakerRoche Molecular Systems Inc., Pleasanton, CA.
Sean BoyleRoche Molecular Systems Inc., Pleasanton, CA.
Shagufta AslamRoche Molecular Systems Inc., Pleasanton, CA.
Ruediger RidderVentana Medical Systems, Inc. (Roche Tissue Diagnostics), Tucson, AZ.
Warner K HuhDivision of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL.
Thomas C WrightDepartment of Pathology, Columbia University, New York City, NY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of our study was to assess the performance of different triage strategies for high-risk human papillomavirus (hrHPV)-positive results utilizing either extended genotyping or a p16/Ki-67 dual-stained cytology (DS) approach, with or without partial genotyping. A subset of women with hrHPV infections participating in the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study were analyzed to determine the number of cervical intraepithelial neoplasia grade 3 or worse (≥CIN3) cases detected, and the absolute risk for ≥CIN3 of each genotype. A clinical utility table was constructed to compare the impact of different triage strategies. In all, 2,339 women with single-genotype hrHPV infections were identified. Among these were 171 ≥CIN3 cases. The U.S. Food and Drug Administration (FDA)-approved algorithm (HPV16/18 positive, or 12-other hrHPV positive and Pap positive, i.e., ≥ atypical squamous cells of undetermined significance) for primary HPV screening detected 132/171 (77.2%) ≥CIN3 cases and required 964 colposcopies (colposcopies per ≥CIN3 ratio: 7.3). An approach that uses DS instead of cytology in the FDA-approved algorithm detected 147/171 (86.0%) ≥CIN3 cases, requiring 1,012 colposcopies (ratio: 6.9). Utilizing DS for triage of all hrHPV-positive women identified 126/171 (73.7%) ≥CIN3 cases, requiring 640 colposcopies (ratio: 5.1). A strategy that detected HPV16/18/31/33/35+ captured 130/171 (76.0%) ≥CIN3 cases, requiring 1,025 colposcopies (ratio: 7.9). Inclusion of additional genotypes resulted in greater disease detection at the expense of higher colposcopy ratios. Substituting cytology with a DS triage approach improved disease detection and the colposcopy detection rate. Further reduction of colposcopy rates can be achieved by using DS without partial genotyping. Extended genotyping strategies can identify a comparable number of cases but requires an increased number of colposcopies.

Indexed as

AdultAgedAged, 80 and overCyclin-Dependent Kinase Inhibitor p16CytodiagnosisDNA, ViralFemaleFollow-Up StudiesGenotypeHumansKi-67 AntigenMass ScreeningMiddle AgedPapillomaviridaePapillomavirus InfectionsPrognosisCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, ViralKi-67 Antigenextended genotypingHPVp16/Ki-67 dual-stained cytologypap cytologytriage

Identifiers

PMID31490545
PMCPMC7078939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.